Lymphoma & Plasma Cell Disorders
News
Ground-breaking therapy comes with distinct challenges
NEW YORK—Two chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel (Yescarta ®) and tisagenlecleucel (Kymriah™)—are already...
News
Two immunologists receive Nobel Prize in medicine
Two immunologists have been awarded the Nobel Prize in Physiology or Medicine for discoveries that represent a “paradigmatic shift in the fight...
News
Brentuximab improves survival in older HL patients
Older patients with untreated Hodgkin lymphoma (HL) can achieve significantly improved survival by adding brentuximab vedotin to their treatment...
News
FDA lifts partial hold on tazemetostat trials
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.
News
FDA authorizes ClonoSEQ to detect MRD in ALL, myeloma
The assay is the first next generation sequencing–based test to be granted marketing approval for detecting minimal residual disease in patients...
Conference Coverage
Prognostic factors guide mantle cell treatment decisions
CHICAGO –
Conference Coverage
CAR T-cell studies dominate ongoing cellular therapy trials
Out of 753 cellular therapy trials listed at ClinicalTrials.gov as of March 30, 2018, 404 were CAR T therapy studies.
News
FDA lifts partial hold on tazemetostat trials
The U.S.
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
Conference Coverage
CAR T may have curative potential in Hodgkin lymphoma
NEW YORK – Early trials point to potential for CD30-specific CAR T-cell therapy.
From the Journals
Outpatient lenalidomide/rituximab yields long-term MCL remission
Nearly two-thirds of evaluable patients with mantle cell lymphoma had durable responses to induction and maintenance.